Analysts lifted targets across tech and life sciences on September 4, with a lone cut standing out in the electronic manufacturing space.
MRVL saw the biggest consensus target jump among chip names. The average analyst target moved to $285.00, up from $284.80. That modest nominal shift belies a market cap of $181 billion and near-universal buy sentiment — 39 of 44 analysts rate it a buy.
NVDA also picked up a target price upgrade. The new consensus lands at $327.13. Sentiment remains overwhelmingly bullish with 57 buy ratings and just three holds.
CRWD got a more meaningful bump. Analysts raised the average target to $231.24 from $226.57. That is a $4.67 increase. Cybersecurity spending remains strong and supports the bullish lean.
The sole downgrade in target price came from FLEX. The average target slipped to $158.33 from $160.50. Short interest in Flex sits at just 2.5% of free float. Bears are not piling in, but analysts are trimming expectations.
RVTY was the standout in life sciences. Revvity's consensus target rose to $125.25 from $122.75 — a 2% gain. The $14.6 billion diagnostics and life science tools firm carries moderate short interest at 6.6% of free float.
PANW rounded out the cybersecurity theme. Target rose to $390.50 from $385.65, with 44 buy ratings backing it.
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
